The Cydan Team
Aileen Healy, PhD
Vice President, Preclinical Development
Aileen Healy brings to Cydan significant experience leading preclinical research in neuroscience, cardiovascular, oncology and inflammation indications.
Prior to joining Cydan Development, Dr. Healy was the Vice President of Research at Seaside Therapeutics, where she was focused on developing treatments to improve the course of fragile X syndrome and autism spectrum disorders. Previously, Dr. Healy held positions of increasing responsibility at Momenta Pharmaceuticals and Millennium Pharmaceuticals. Her prior preclinical research in drug discovery and development included significant contributions to target identification, lead optimization, in vivo pharmacology and biomarker discovery for small molecules and biologics. Earlier in her career, Dr. Healy was a faculty member at Boston University School of Medicine, where her research focused on cellular and molecular mechanisms of pulmonary development and disease. Dr. Healy holds patents and has published in peer-reviewed journals on a wide range of topics.
Dr. Healy received her PhD from Tufts University and postdoctoral training from Massachusetts Institute of Technology.